New Four-Target cancer antibody enters first human trials
NCT ID NCT04794972
Summary
This is an early-stage study to test the safety and initial effects of a new experimental drug called GNC-039 in adults with advanced solid tumors that have returned or spread after standard treatments. The main goals are to find a safe dose and see what side effects occur. Researchers will also check if the drug shows any early signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, China
Contact
Contact
Contact
Contact
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shenzhen Second People's Hospital
RECRUITINGShenzhen, Guangdong, China
Contact
-
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITINGXian, Shanxi, China
Contact
-
West China Hospital，Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact
-
ZhuJiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.